A new era of antibody discovery: an in-depth review of AI-driven approaches

Drug Discov Today. 2024 Apr 18:103984. doi: 10.1016/j.drudis.2024.103984. Online ahead of print.ABSTRACTGiven their high affinity and specificity for a range of macromolecules, antibodies are widely used in the treatment of autoimmune diseases, cancers, inflammatory diseases, and Alzheimer's disease (AD). Traditional experimental methods are time-consuming, expensive, and labor-intensive. Recent advances in artificial intelligence (AI) technologies provide complementary methods that can reduce the time and costs required for antibody design by minimizing failures and increasing the success rate of experimental tests. In this review, we scrutinize the plethora of AI-driven methodologies that have been deployed over the past 4 years for modeling antibody structures, predicting antibody-antigen interactions, optimizing antibody affinity, and generating novel antibody candidates. We also briefly address the challenges faced in integrating AI-based models with traditional antibody discovery pipelines and highlight the potential future directions in this burgeoning field.PMID:38642702 | DOI:10.1016/j.drudis.2024.103984
Source: Drug Discovery Today - Category: Drugs & Pharmacology Authors: Source Type: research